CSO

Veyond Metaverse Revolutionizes XR Digital Surgery with New AI Voice Command Technology

Retrieved on: 
Monday, November 27, 2023

San Francisco, California--(Newsfile Corp. - November 27, 2023) - Veyond Metaverse, a trailblazer in extended reality (XR) healthcare technology, announces a development in digital surgery - the introduction of an AI-powered voice command system that works in tandem with dynamic digital twins in XR operating environments.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - November 27, 2023) - Veyond Metaverse, a trailblazer in extended reality (XR) healthcare technology, announces a development in digital surgery - the introduction of an AI-powered voice command system that works in tandem with dynamic digital twins in XR operating environments.
  • The AI voice command feature is poised to enhance the dynamics within XR operating rooms significantly.
  • "Our journey in transforming digital surgery has been fundamentally driven by advanced AI and XR technology," stated Joon Chung, CTO and Co-Founder of Veyond Metaverse.
  • Incorporating AI voice command technology in our XR operating rooms is a crucial enhancement that empowers healthcare professionals globally."

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

Retrieved on: 
Thursday, December 28, 2023

Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.

Key Points: 
  • Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.
  • Earlier this year the FDA approved the first medicine for the treatment of GA, SYFOVRE®1 (pegcetacoplan injection) from Apellis.
  • In August of this year, a second product was approved for GA, IZERVAY™2(avacincaptad pegol intravitreal solution) from Iveric Bio, an Astellas company, with a similar profile to SYFOVE.
  • In the event the total Working Capital costs would amount to the total remaining amount under the Atlas funding program, i.e.

Credicorp LTD.: Credicorp Announces Executive Leadership Changes Effective July 1, 2024

Retrieved on: 
Thursday, December 21, 2023

Moreover, Michelle Labarthe Wiese, joins Credicorp as Chief Strategy Officer (CSO), a newly created position that will oversee the Sustainability, Strategy & Corporate Development, and M&A functions, effective January 2nd, 2024.

Key Points: 
  • Moreover, Michelle Labarthe Wiese, joins Credicorp as Chief Strategy Officer (CSO), a newly created position that will oversee the Sustainability, Strategy & Corporate Development, and M&A functions, effective January 2nd, 2024.
  • Cesar Ríos Briceño, currently CFO of Credicorp and BCP, was appointed CRO of Credicorp and BCP replacing Reynaldo Llosa Benavides who has tendered his resignation effective June 30, 2024.
  • Alejandro Pérez-Reyes Zarak, currently COO of Credicorp, has been appointed as CFO of Credicorp, effective July 1, 2024, replacing Mr. Ríos Briceño.
  • After these changes, Credicorp will have a total of 25% of its senior management leadership represented by women, up from 20%.

ROHM Completes Demonstration of Manufacturing Process Optimization by Applying Quanmatic's Quantum Technology

Retrieved on: 
Thursday, December 14, 2023

This represents the world's first demonstration of manufacturing process optimization using quantum technology in a large-scale mass production line at a semiconductor manufacturing plant.

Key Points: 
  • This represents the world's first demonstration of manufacturing process optimization using quantum technology in a large-scale mass production line at a semiconductor manufacturing plant.
  • In recent years, the use of quantum technology has been explored in various fields, in particular quantum annealing methods [2] being introduced in the area of combinatorial optimization, such as for delivery route optimization in the logistics industry.
  • At the same time, in the semiconductor industry, as the manufacturing process becomes more extensive the possible combinations increase exponentially.
  • The development of an operational system suitable for large-scale mass production lines using quantum technology represents a major step forward for the semiconductor manufacturing industry, enabling real-time optimization of production processes.

Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform

Retrieved on: 
Thursday, December 14, 2023

The $20.6M (CHF 18M) round was led by ND Capital together with a small syndicate of HNW private investors.

Key Points: 
  • The $20.6M (CHF 18M) round was led by ND Capital together with a small syndicate of HNW private investors.
  • Vandria was spun out of Amazentis SA in 2021 with backing by ND Capital to develop first-in-class small molecule mitophagy inducers against a novel target to rejuvenate cells and treat age-related and chronic diseases.
  • Penelope Andreux, CSO of Vandria, said: “The potential of mitophagy as a new therapeutic approach for tackling CNS disorders is increasingly recognised by the pharmaceutical industry.
  • We have worked closely with the company to assemble a world-class leadership team and attract high-calibre advisors and additional investors.

ON Partners 2023 Variance Report Validates CEO & C-Suite Pay Disparities Grow with Company Size

Retrieved on: 
Wednesday, December 13, 2023

CLEVELAND, Dec. 13, 2023 (GLOBE NEWSWIRE) -- ON Partners , a pure-play retained executive search firm building diverse C-level and board leadership teams, published its 2023 Variance Report .

Key Points: 
  • CLEVELAND, Dec. 13, 2023 (GLOBE NEWSWIRE) -- ON Partners , a pure-play retained executive search firm building diverse C-level and board leadership teams, published its 2023 Variance Report .
  • The report delves into major shifts impacting the business world, including average compensation rates by company size, geo-market hiring demand, and industry sectors experiencing the greatest shifts in talent management strategies.
  • “This year’s Variance Report leverages transparency and data innovation, specifically as it relates to overall compensation for the executive marketplace,” said Tim Conti, Co-President of ON Partners.
  • To learn more about ON’s approach and additional findings within this year’s Variance Report, visit https://onpartners.com/contact-executive-recruitment-agency/ .

Recalls are up 115% since 2018, New MasterControl Study Finds

Retrieved on: 
Wednesday, December 13, 2023

“The first step in creating change is understanding what issues to focus on which is what we hope this data provides.

Key Points: 
  • “The first step in creating change is understanding what issues to focus on which is what we hope this data provides.
  • We’re seeing that there are problem areas like allergens and categories like infant products that get flagged frequently,” said Matt Lowe, chief strategy officer (CSO) at MasterControl.
  • More than 1 in 5 FDA recalls since 2018 were driven by process and contamination concerns.
  • There were twice as many recalls on pet food and animal products in the past five years than those issued on baby formula.

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04

Retrieved on: 
Wednesday, December 13, 2023

The multiple-arm, multicentre, prospective, randomized, double-blind, placebo-controlled Phase II study enrolled more than 500 participants with pain due to osteoarthritis of the knee ( ClinicalTrials.gov ID: NCT05618782 ).

Key Points: 
  • The multiple-arm, multicentre, prospective, randomized, double-blind, placebo-controlled Phase II study enrolled more than 500 participants with pain due to osteoarthritis of the knee ( ClinicalTrials.gov ID: NCT05618782 ).
  • The trial was designed to evaluate the efficacy, safety and tolerability of five, monthly, infusions of LEVI-04 as compared to placebo in participants with radiographic and symptomatic knee osteoarthritis.
  • It operates across four receptor pathways in the neurotrophin system and is designed to supplement the existing endogenous p75NTR binding protein and returning normal neurotrophin function.
  • While the potential of the neurotrophin pathway to provide effective pain relief is recognised, safety issues have significantly hampered development.

Caveonix Appoints Aloysius Boyle as New CEO to Drive Next Phase of Growth

Retrieved on: 
Tuesday, December 12, 2023

Boyle is a widely respected industry executive with nearly two decades of experience in the technology and cybersecurity industry.

Key Points: 
  • Boyle is a widely respected industry executive with nearly two decades of experience in the technology and cybersecurity industry.
  • Boyle has successfully spearheaded growth initiatives at multiple top security technology companies.
  • "We are delighted to welcome Ish Boyle to the Caveonix family," said Kaus Phaltankar, Co-Founder and Chairman of the Board at Caveonix.
  • We believe his leadership will drive innovation and growth that benefits our customers, partners, and stakeholders."

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

Retrieved on: 
Monday, December 11, 2023

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
  • “We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
  • “We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
  • Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”